Table 1

Demographic data, type of cancer and ICI molecules

Characteristics at baselinen (%)
Age, mean (SD)64.5 (12.8)
 Gender
  Male360 (68.7)
  Female164 (31.3)
Tumour type
 Melanoma239 (45.6)
 Merkel5 (1.0)
 Lung129 (24.6)
 Renal71 (13.5)
 Urothelial14 (2.7)
 Head and neck29 (5.5)
 Blood cancer15 (2.9)
 Gastrointestinal/liver18 (3.4)
 Lung+head and neck3 (0.6)
 Glioblastoma1 (0.2)
Cancer therapy
 Anti-CTLA-4 5 (1.0)
  Ipilimumab3 (0.6)
  Tremelimumab2 (0.3)
 Anti-PD-1 337 (64.3)
  Nivolumab225 (42.9)
  Pembrolizumab112 (21.4)
 Anti-PD-L1 70 (13.3)
  Avelumab25 (4.8)
  Atezolizumab23 (4.4)
  Durvalumab18 (3.4)
  MSB0011359C4 (0.7)
 Sequential or combined 112 (21.4)
  • CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ICI, immune checkpoint inhibitor; PD-1, programmed cell death protein 1.